CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case …
2024年2月21日 · We evaluated 15 patients with severe SLE (8 patients), idiopathic inflammatory myositis (3 patients), or systemic sclerosis (4 patients) who received a single infusion of CD19 chimeric antigen...
CD19-targeted CAR T-cell therapeutics for hematologic …
2016年6月30日 · Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B-cell malignancies.
A safe and potent anti-CD19 CAR T cell therapy - Nature
2019年4月22日 · Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cause severe cytokine-release syndrome (CRS) and neurotoxicity, impeding their therapeutic application. Here we generated a new...
mRNA-Laden Lipid-Nanoparticles-Enabled CD19 CAR-T Cells …
2024年11月5日 · In this study, we developed an innovative approach for engineering CD19 CAR-T cells using mRNA-LNPs, and the anti-leukemic cells effects of CAR-T cells were validated in both in vitro and in vivo settings. Methods: With microfluidic technology, the mRNA encoding the full humanized anti-CD19 CAR was encapsulated into mRNA-lipid nanoparticles ...
CD19 CAR T Cells - Cell Press
2017年12月14日 · CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
CAR T cells: building on the CD19 paradigm - PMC - PubMed …
CD19-targeted chimeric antigen receptors (CD19 CARs) have opened a path for novel immune therapies in oncology and other fields of medicine. This therapeutic innovation is predicated on advances in genetic engineering, tumor immunology and cell manufacturing sciences [1 – 4].
CAR T cells with dual targeting of CD19 and CD22 in adult
2021年7月26日 · To prevent relapse with CD19 − or CD19 lo disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial (NCT03233854) of adults with...
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR ...
2021年6月22日 · We developed a humanized CD19 CAR based on the backbone of CTL019 (now known as tisagenlecleucel), with the hypothesis that it would have a lower risk of immunogenicity than a murine-based CAR and show improved persistence.
Anti-CD19 CAR T-cell therapy for primary and secondary CNS
2024年12月14日 · The recent approval of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for systemic B-cell lymphomas has shifted the treatment landscape for previously incurable patients. Even though ...
CD19 CAR antigen engagement mechanisms and affinity tuning
2023年3月10日 · We report cryo-EM structures of CD19 antigen with the binder FMC63, which is used in four FDA-approved CAR T cell therapies (Kymriah, Yescarta, Tecartus, and Breyanzi), and the binder SJ25C1, which has also been used extensively in multiple clinical trials.
CD19-targeting CAR T-cell therapy in patients with diffuse …
2024年11月11日 · CD19-targeting CAR T-cell treatment appears to be a potent tool to inhibit immune-driven activation of fibroblasts as it depletes B cells from the early pro-B-cell state up to antibody-producing plasmablasts.
CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed …
CD19-targeted CAR T cells have induced complete remissions of disease in up to 90% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), who have an expected complete response rate of 30% in response to chemotherapy.
CD19-CAR Trials - PMC - National Center for Biotechnology …
CD19 is a B-lineage specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs).
CAR T Cells: Engineering Immune Cells to Treat Cancer
Although CD19 and BCMA are the only antigens for which there are FDA-approved CAR T-cell therapies, CAR T-cell therapies have been developed that target other antigens commonly found in blood cancers, including therapies that target multiple antigens at one time.
CAR therapy: the CD19 paradigm - PMC
This review focuses on how CD19 chimeric antigen receptors (CARs) came to be and what we’ve learned, to date, about CAR therapy owing to the CD19 paradigm. Back in the late 1980s, the rationale for T cell engineering was to rapidly establish a potent immune attack on cancer cells.
Two years later: CD19 CAR-T going the distance | Blood
2024年2月1日 · In this issue of Blood, Abramson et al 1 present follow-up data from TRANSCEND, redemonstrating robust and ongoing responses from the largest pivotal cohort of CD19 chimeric antigen receptor (CAR)-T–treated patients to date.
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T …
2020年10月6日 · Anti-CD19 chimeric antigen receptors (CARs) are artificial fusion proteins that cause CD19-specific T-cell activation. Durability of remissions and incidence of long-term adverse events are critical factors determining the utility of anti-CD19 CAR T-cell therapy, but long-term follow-up of patients treated with anti-CD19 CAR T cells is limited.
A safe and potent anti-CD19 CAR T cell therapy - PubMed
Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cause severe cytokine-release syndrome (CRS) and neurotoxicity, impeding their therapeutic application. Here we generated a new anti-CD19 CAR molecule (CD19-BBz (86)) derived from the CD19-BBz prototype bearing co-stimulatory 4-1BB and CD3ζ domains.
Immunological effects of CD19.CAR-T cell therapy in systemic …
2024年12月13日 · The high potential of CD19.CAR-T cells to treat autoimmune diseases such as Systemic Sclerosis (SSc) supposedly relies on the disappearance of autoantibodies. Here we investigated effects of CAR-T cells on the innate immune system which is an important contributor to pathology in SSc. Longitudinal analysis of peripheral blood mononuclear cells from an Scl70 …
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018年1月31日 · CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions...
Use of CAR-Transduced Natural Killer Cells in CD19-Positive …
2020年2月5日 · Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture...
Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in …
This CAR platform, known as CoupledCAR, consists of CAR T cells targeting a specific solid tumor antigen, such as GCC CAR T cells directed against GCC, and 3 subpopulations of CD19 CAR T cells, each engineered to express either IFN-γ, IL-6, or IL-12 in a single product (eFigure 1 in Supplement 1). This report describes the safety and ...
Baseline echocardiographic variables as predictors of …
4 天之前 · Background CD19 CAR T-cell therapy is a novel anti-cancer treatment that has produced remarkable responses in relapsed or refractory B-cell hematological malignancies. Cytokine Release Syndrome (CRS) is a dysregulated immune response that frequently occurs after CAR T-cell infusion. It can cause cardiac dysfunction and circulatory collapse negatively …
CD19-CAR trials - PubMed
This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). Here, we review published phase 1 trials of T cells expressing CARs targeting CD19 and describe briefly the biological questions that they addressed.
Advances in CAR-T cell therapy for hematologic and solid …
2024年12月5日 · A real-world study from the French DESCAR-T registry confirmed previous efficacy data from the pivotal ELARA trial, showing that with a median follow-up of 9.8 months, CD19 CAR-T therapy with tisagenlecleucel in 129 cases of R/R follicular lymphoma achieved a 98.2% ORR, including 85.8% best CR, with only 1.8% experiencing progression as the ...
Preclinical development of three novel CARs targeting CD79b for …
Background Infusion of T cells modified with a chimeric antigen receptor (CAR) targeting CD19 has achieved exceptional responses in patients with non-Hodgkin’s lymphoma (NHL), which led to the approval of CAR targeting CD19 (CART19) (Axi-cel and Liso-cel) as second line of treatment for adult patients with relapsed/refractory NHL. Unfortunately, 60% of patients still relapse after …
Anti-CD19 CAR T cell therapy for refractory systemic lupus ...
Autologous T cells from patients with SLE were transduced with a lentiviral anti-CD19 CAR vector, expanded and reinfused at a dose of 1 × 10 6 CAR T cells per kg body weight into the patients after lymphodepletion with fludarabine and cyclophosphamide. CAR T cells expanded in vivo, led to deep depletion of B cells, improvement of clinical ...
Efficacy and safety of CD19-directed CAR-T cell therapies in
2021年10月1日 · Chimeric antigen receptor (CAR)-T cell therapies have improved the outcome for many patients with relapsed or refractory aggressive B-cell lymphomas. In 2017, axicabtagene ciloleucel and soon after tisagenlecleucel became the first approved CAR-T cell products for patients with high-grade B-cell lym …
Novel Neurocognitive Testing Tool for Early Neurotoxicity …
2 天之前 · We assessed the utility of a rapid, targeted neurocognitive testing tool (CART-NS) in the early detection of ICANS and its ability to predict a priori which patients will develop this toxicity following CAR T-cell therapy. Twelve patients underwent CART-NS testing during the first 30 days after infusion for a total of 862 test administrations, along with serum biomarker testing.
TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells …
2021年8月13日 · In vitro, CD19 CAR-tTRII-I7R-T cells had a lower level of phosphorylated SMAD2 and a higher level of target-specific cytotoxicity than controls in the presence of rhTGF-β1. In the animal model, the overall survival and recurrence-free survival of mice that received CD19 CAR-tTRII-I7R-T cells were significantly longer than in control mice.